BLLN Stock Analysis: BillionToOne, Common Stock | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 5.536m USD | 12M Return: 26.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 83.8M
Rev. Trend: 100.0%
Warnings
Tailwinds
Seasonality 0.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BillionToOne, Inc. (NASDAQ: BLLN) is a U.S.-based precision diagnostics company headquartered in Menlo Park, California, and founded in 2016. It operates in the health care sector, with a business model focused on molecular diagnostics - an area of laboratory medicine that analyzes DNA, RNA, and other biomarkers to detect disease, guide treatment, and monitor patient response. The company went public on November 6, 2025, and is classified as a mid-cap stock.
The companys core technology is a molecular counting platform designed to detect and quantify DNA molecules at the single-molecule level, which underpins its three commercial test lines. UNITY Complete is a non-invasive prenatal screen (NIPS) that uses a maternal blood draw to assess fetal risk for aneuploidies, recessive conditions, and fetal antigens. Northstar Select and Northstar Response are oncology-focused liquid biopsy tests - a category of diagnostics that analyzes blood samples to identify tumor-derived material, eliminating the need for invasive tissue sampling in some cases.
BillionToOnes commercial focus spans reproductive health and oncology, two high-growth segments within the broader molecular diagnostics market. Its prenatal screening product competes in the non-invasive prenatal testing (NIPT) space, while its liquid biopsy offerings target the rapidly expanding market for blood-based cancer detection and treatment monitoring, areas that have seen increased adoption as payers and providers seek less invasive diagnostic alternatives.
- UNITY Complete prenatal test volume drives revenue growth
- Northstar Response liquid biopsy gains oncologist adoption
- Competition from Natera pressures prenatal market share and pricing
| Net Income: 25.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 21.49 > 1.0 |
| NWC/Revenue: 159.9% < 20% (prev 109.9%; Δ 50.03% < -1%) |
| CFO/TA 0.05 > 3% & CFO 38.1m > Net Income 25.2m |
| Net Debt (-339.1m) to EBITDA (40.9m): -8.30 < 3 |
| Current Ratio: 10.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.0m) vs 12m ago 18.58% < -2% |
| Gross Margin: 70.40% > 18% (prev 57.35%; Δ 13.05% > 0.5%) |
| Asset Turnover: 69.97% > 50% (prev 57.13%; Δ 12.84% > 0%) |
| Interest Coverage Ratio: 464.9 > 6 (EBIT TTM 30.2m / Interest Expense TTM 65.0k) |
| A: 0.81 (Total Current Assets 624.1m - Total Current Liabilities 57.2m) / Total Assets 700.7m |
| B: -0.37 (Retained Earnings -256.8m / Total Assets 700.7m) |
| C: 0.06 (EBIT TTM 30.2m / Avg Total Assets 506.7m) |
| D: 2.59 (Book Value of Equity 505.6m / Total Liabilities 195.1m) |
| Altman-Z'' = 7.24 = AAA |
| DSRI: 1.01 (Receivables 61.3m/30.4m, Revenue 354.5m/178.6m) |
| GMI: 0.81 (GM 57.35% / 70.40%) |
| AQI: 0.27 (AQ_t 0.01 / AQ_t-1 0.03) |
| SGI: 1.98 (Revenue 354.5m / 178.6m) |
| TATA: -0.02 (NI 25.2m - CFO 38.1m) / TA 700.7m) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 126.77 with a total of 797,718 shares traded. Over the past week, the price has changed by +5.33%, over one month by +27.72%, over three months by +56.26% and over the past year by +26.73%.
Current recommended Stop Loss: 116.70 (which is 7.9% or 1.4 ATR below the current price).
BillionToOne, Common Stock has no consensus analysts rating.
P/E Trailing = 222.8704
P/S = 15.6135
P/B = 11.1282
Revenue TTM = 354.5m USD
EBIT TTM = 30.2m USD
EBITDA TTM = 40.9m USD
Long Term Debt = 90.0m USD (from longTermDebt, last quarter)
Short Term Debt = 6.24m USD (from shortTermDebt, last quarter)
Debt = 198.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 54.2m
Net Debt = -339.1m USD (calculated: Debt 198.4m - CCE 537.5m)
Enterprise Value = 5.20b USD (5.54b + Debt 198.4m - CCE 537.5m)
Interest Coverage Ratio = 464.9 (Ebit TTM 30.2m / Interest Expense TTM 65.0k)
EV/FCF = 113.6x (Enterprise Value 5.20b / FCF TTM 45.7m)
FCF Yield = 0.88% (FCF TTM 45.7m / Enterprise Value 5.20b)
FCF Margin = 12.90% (FCF TTM 45.7m / Revenue TTM 354.5m)
Net Margin = 7.11% (Net Income TTM 25.2m / Revenue TTM 354.5m)
Gross Margin = 70.40% ((Revenue TTM 354.5m - Cost of Revenue TTM 105.0m) / Revenue TTM)
Gross Margin QoQ = 72.97% (prev 71.42%)
Tobins Q-Ratio = 7.42 (Enterprise Value 5.20b / Total Assets 700.7m)
Interest Expense / Debt = 0.03% (Interest Expense 65.0k / Debt 198.4m)
Taxrate = 2.47% (744k / 30.2m)
NOPAT = 29.5m (EBIT 30.2m * (1 - 2.47%))
Current Ratio = 9.48 (Total Current Assets 624.1m / Total Current Liabilities 65.9m)
Debt / Equity = 0.39 (Debt 198.4m / totalStockholderEquity, last quarter 505.6m)
Debt / EBITDA = -8.30 (Net Debt -339.1m / EBITDA 40.9m)
Debt / FCF = -7.41 (Net Debt -339.1m / FCF TTM 45.7m)
Total Stockholder Equity = 333.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.98% (Net Income 25.2m / Total Assets 700.7m)
RoE = 7.55% (Net Income TTM 25.2m / Total Stockholder Equity 333.7m)
RoCE = 7.13% (EBIT 30.2m / Capital Employed (Equity 333.7m + L.T.Debt 90.0m))
RoIC = 4.66% (NOPAT 29.5m / Invested Capital 632.1m)
WACC = 10.53% (E(5.54b)/V(5.73b) * Re(10.91%) + D(198.4m)/V(5.73b) * Rd(0.03%) * (1-Tc(0.02)))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.55 | Cagr: 8.89%
[DCF] Terminal Value 68.18% ; FCFF base≈45.7m ; Y1≈45.9m ; Y5≈48.7m
[DCF] Fair Price = 21.50 (EV 551.9m - Net Debt -339.1m = Equity 891.0m / Shares 41.4m; r=10.53% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.97 | Revenue CAGR: 106.2% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+45.45% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=+28.95% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.87 | Chg30d=+72.28% | Revisions=+25% | GrowthEPS=+66.5% | GrowthRev=+48.8%
EPS next Year (2027-12-31): EPS=1.03 | Chg30d=+15.08% | Revisions=-25% | GrowthEPS=+18.4% | GrowthRev=+27.1%
[Analyst] Revisions Ratio: +0% (up=2, down=2)